BIXINK

Notifications

Back

Notification settings

Back

Post notifications

Be notified when someone leaves a comment or a reply to your post or comment.

Updates and news

Stay ahead of important updates and news from the site.

Alarm
My account Sign out

Vision
Mission
Greeting
Our people

CANCER THERAPEUTICS

Nerlynx®
MUCOSAMIN™

DIGITAL THERAPEUTICS

OC Free ™
WEPEACH ™

Press Release
IR

Location
Inquiry

한국어
English

CANCER THERAPEUTICS

DIGITAL THERAPEUTICS

Vision
Mission
Greeting
Our people

CANCER THERAPEUTICS

Nerlynx®
MUCOSAMIN™

DIGITAL THERAPEUTICS

OC Free ™
WEPEACH ™

Press Release
IR

Location
Inquiry

한국어
English

한국어
English

MEDIA

Press Release
IR

Press Release

No
Title
Author
Time uploaded
Views
Likes

12
Nerlynx in HER2-positive Early Breast Cancer, helping to overcome the fear of Recurrence
Halimriadi Richar
11 May 2022
Views51
1

11
Blue Note Therapeutics and Bixink Enter Licensing Agreement for attune™ and DreAMLand™, Prescription Digital Therapeutics for Mental Well-Being in Cancer Patients
Halimriadi Richar
10 May 2022
Views63
0

10
BIXINK " Breast cancer supplement Nerlynx is available in hospitals"
Halimriadi Richar
9 May 2022
Views59
1

9
BIXINK develops Korea's First Digital Therapeutics for mental disorder in cancer patients
Halimriadi Richar
2 May 2022
Views110
1

8
BIXINK signed contract with Taiwanese pharma company for Mucosamin, product for oral mucositis management in cancer patients
Halimriadi Richar
9 Feb 2022
Views170
0

7
BIXINK "Reimbursement for Nerlynx anticipated next year"
Halimriadi Richar
9 Feb 2022
Views161
0

6
BIXINK obtains market authorization of Nerlynx in Korea for early breast cancer
이창희
21 Oct 2021
Views286
0

5
LIMBIX, an invested company of BIXINK, launches SparkRx under the U.S FDA Emergency Use Authorization
이창희
7 Oct 2021
Views241
0

4
Bixink, as a first Korean company, to initiate study for its digital therapeutics device “OC FREE” in the U.S. soon
이창희
5 Aug 2021
Views149
0

3
Bixink Therapeutics and Professional Dietetics enter into partnership for the MUCOSAMIN® range, onco-supportive care, whereby Bixink will hold the exclusive distribution rights in the Asian region
이창희
5 Aug 2021
Views107
0

Previous
1
2
Next

Copyright 2021 - BIXINK │ Terms of Use

Contact │ Privacy

6F, 292 Gangnam-daero, Gangnam-gu, Seoul 06258,

Republic of Korea

Copyright 2021 - BIXINK │ Terms of Use │ Contact │ Privacy

6F, 292 Gangnam-daero, Gangnam-gu, Seoul 06258, Republic of Korea